Nurix Therapeutics (NASDAQ:NRIX) PT Raised to $31.00 at Barclays
Nurix Therapeutics (NASDAQ:NRIX – Free Report) had its price objective raised by Barclays from $20.00 to $31.00 in a research report report published on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock. A number of other analysts have also recently weighed in on the stock. JPMorgan Chase & Co. […]
More Stories
Philip Morris International Inc. (NYSE:PM) Short Interest Up 21.7% in October
Philip Morris International Inc. (NYSE:PM – Get Free Report) was the recipient of a significant growth in short interest during...
Global X Clean Tech ETF (NASDAQ:CTEC) Short Interest Up 26.0% in October
Global X Clean Tech ETF (NASDAQ:CTEC – Get Free Report) saw a significant increase in short interest in the month...
Latham Group, Inc. (NASDAQ:SWIM) Sees Large Growth in Short Interest
Latham Group, Inc. (NASDAQ:SWIM – Get Free Report) was the target of a significant growth in short interest in October....
Daito Trust Construction Co.,Ltd. (OTCMKTS:DIFTY) Short Interest Update
Daito Trust Construction Co.,Ltd. (OTCMKTS:DIFTY – Get Free Report) was the recipient of a large drop in short interest during...
Jaguar Health, Inc. (NASDAQ:JAGX) Short Interest Up 138.4% in October
Jaguar Health, Inc. (NASDAQ:JAGX – Get Free Report) saw a large growth in short interest in October. As of October...
Contrasting Wetouch Technology (NASDAQ:WETH) and Siebert Financial (NASDAQ:SIEB)
Profitability This table compares Siebert Financial and Wetouch Technology’s net margins, return on equity and return on assets. Net Margins...